Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.

[1]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[2]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[3]  C. Kensil,et al.  Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. , 1994, AIDS research and human retroviruses.

[4]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[5]  R. Siliciano,et al.  Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine , 1994, Journal of virology.

[6]  J. Y. Wu,et al.  Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 viral peptides to nonhuman primate lymphocytes in proliferation and cytotoxic T-lymphocyte assays. , 1994, Clinical and diagnostic laboratory immunology.

[7]  M. Kieny,et al.  Strain specificity of cell-mediated cytotoxic responses specific for the human immunodeficiency virus type 1 (HIV-1) envelope protein in seropositive donors: HIV-1Lai is more commonly recognized than HIV-1MN. , 1994, The Journal of infectious diseases.

[8]  D. Ho,et al.  Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope , 1994, The Journal of experimental medicine.

[9]  N. Roberts,et al.  Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. , 1993, The Journal of infectious diseases.

[10]  S. Chang,et al.  Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes , 1993, Journal of virology.

[11]  M. McElrath,et al.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Walker,et al.  Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone , 1993, Journal of virology.

[13]  R. Siliciano,et al.  Comparative clonal analysis of human immunodeficiency virus type 1 (HIV- 1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines , 1992, The Journal of experimental medicine.

[14]  M. Champe,et al.  Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1 , 1992, Journal of virology.

[15]  J. Levy,et al.  CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. , 1992, AIDS research and human retroviruses.

[16]  B. Walker,et al.  Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation , 1992, The Journal of experimental medicine.

[17]  C. Kensil,et al.  Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. , 1992, Journal of immunology.

[18]  R A Houghten,et al.  Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. , 1992, Science.

[19]  B. Haynes,et al.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Berzofsky,et al.  Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. , 1991, The Journal of clinical investigation.

[21]  S. Chada,et al.  Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. , 1991, AIDS research and human retroviruses.

[22]  J. Berzofsky,et al.  Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. , 1991, Journal of immunology.

[23]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[24]  D. Nixon,et al.  High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. , 1990, International immunology.

[25]  M. McGrath,et al.  Effects of GLQ223 on HIV replication in human monocyte/macrophages chronically infected in vitro with HIV. , 1990, AIDS research and human retroviruses.

[26]  T. Masuda,et al.  Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro , 1990, Journal of virology.

[27]  B. Walker,et al.  Techniques in HIV Research , 1990, Palgrave Macmillan UK.

[28]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.

[29]  G. Gaudernack,et al.  CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. , 1990, Journal of immunology.

[30]  J. Berzofsky,et al.  An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself , 1990, The Journal of experimental medicine.

[31]  J. Berzofsky,et al.  A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. , 1989, Science.

[32]  C. DeLisi,et al.  T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. , 1989, International immunology.

[33]  G. Nakamura,et al.  Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160 , 1989, Journal of virology.

[34]  E. Lennette,et al.  Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections , 1989 .

[35]  J. Berzofsky,et al.  Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals , 1989, Nature.

[36]  B. Autran,et al.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. , 1989, Journal of immunology.

[37]  P. Earl,et al.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. DeLisi,et al.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Walker,et al.  HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. , 1988, Science.

[40]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[41]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[42]  R. Siliciano,et al.  Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. , 1994, AIDS research and human retroviruses.

[43]  A. Burny,et al.  Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual. , 1994, AIDS research and human retroviruses.

[44]  B. Walker,et al.  Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural proteins. , 1994, Current topics in microbiology and immunology.

[45]  C. Czerkinsky,et al.  Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides. , 1993, Vaccine.

[46]  F. Plata.  Implications of HIV specific cytotoxic T lymphocytes in AIDS , 1992, Biotherapy.

[47]  M. Popovič,et al.  Virus Isolation and Production , 1990 .